EU/EEA, European Union / European Economic Area; GBD,Global Burden of Disease; UI,Uncertainty Interval.

*Results from a systematic review, 44 studies were included consisting of 19 observational/retrospective studies, 21 cost-effectiveness studies and 4 studies
with a mixed design (i.e., internet questionnaire, surveys, pooled analysis of several studies, health cost analysis).
The selected studies were conducted in 22 countries, most of them in Europe (n = 28), followed by Asia and Middle East (n = 6), South America (n = 5)
and North America (n = 3)

References:

1. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER).
   CBER clinical review of studies submitted in support of licensure of ProQuad. https://www.fda.gov/media/165978/download. Accessed July 2026.
2. Wu Z, Zhang J, Wei J, Huang C, Xu W, Wu J, Jiang M. Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend
   analysis in the era of the COVID-19 pandemic and projections to 2036. Frontiers in Public Health. 2025 Dec 5;13:1654535.
3. World Health Organization (WHO). Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014; 89 (25): 265– 287.
4. European Centre for Disease Prevention and Control. Varicella vaccination in the European Union. 2015. Accessed July, 2026.
   https://www.ecdc.europa.eu/en/publicationsdata/ public-health-guidance-varicella-vaccination-european-union
5. Williame I, George M, Shah HA, Homer N, Alderson D, Jamet N. Healthcare resource use and costs of varicella and its complications: A systematic literature
   review. Human Vaccines & Immunotherapeutics. 2023 Dec 15;19(3):2266225

AE-QDX-00012 | Exp: 25 July 2028